Fulvestrant Injection, Solution
Product Images NDC 43598-262

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Fulvestrant (NDC 43598-262). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Dr.reddy's Laboratories Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure10 (Figure10)

FDA Label Image

Figure8

FDA Label Image

Carton (Carton)

Fulvestrant Injection is a medication available in the form of two single-dose prefilled syringes, each containing 250 mg/5 mL (50 mg/mL) and two SurGuard 3 Safety shielding intramuscular injection needles. The medication is used through intramuscular use only and needs to be discarded after use. Each syringe must be received to get the 500 mg dose. The GTIN number is 343808262021, and the NDC number is 43598-262-02. The medication needs to be refrigerated at 2° to 8°C (36° to 46°F) and stored in the original carton until the time of use to protect it from light. The text suggests that the medication is manufactured in India.*

FDA Label Image

Figure1 (Figure1)

FDA Label Image

Figure2 (Figure2)

FDA Label Image

Figure4 (Figure4)

FDA Label Image

Figure5 (Figure5)

The text format does not provide a clear understanding of its purpose or context. Therefore, a useful description cannot be generated.*

FDA Label Image

Figure9 (Figure9)

FDA Label Image

Graph11

FDA Label Image

Graph12

This is a graph showing survival probability over time for two groups of patients. The first group of 446 patients were treated with Fulvestrant plus Abemaciclib, while the second group of 223 patients received Fulvestrant plus Placebo. The X-axis represents time in months and the Y-axis represents survival probability. The number of patients at risk is also shown for each group at various time points.*

FDA Label Image

Graph13

FDA Label Image

Graph14

This is a clinical trial report showing the results of a study comparing the effectiveness of RUVETRAN bocic (1 484) versus RUVESTRAT Placebo (V = 242) in treating something related to a health condition. The study tracks the probability of an event occurring over a span of time, shown on a graph where the x-axis is in months. The numbers on the y-axis represent the number of participants in the study. The data shows that RUVETRAN bocic outperforms the placebo over time in reducing the probability of the event occurring.*

FDA Label Image

Pfs (Pfs)

The text is not readable.*

FDA Label Image

Step1 (Step1)

FDA Label Image

Step2 (Step2)

FDA Label Image

Step3 (Step3)

This is a list of different types of activation methods including Finger Activation, Thumb Activation and Surface Activation. No further information is available.*

FDA Label Image

Step4 (Step4)

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.